Mechanisms of Incretin Effects on Plasma Lipids and Implications for the Cardiovascular System

Title:Mechanisms of Incretin Effects on Plasma Lipids and Implications for the Cardiovascular System

Volume: 10 Issue: 4

Author(s): Changting Xiao, Satya Dash and Gary F. Lewis

Affiliation:

Keywords: Apolipoprotein B-100, apolipoprotein B-48, cardiovascular disease, chylomicron, dipeptidyl peptidase-4, dyslipidemia, glucagon-like peptide-1, incretin-based therapies, triglyceride-rich lipoprotein, triglycerides, type 2 diabetes, very low-density lipoprotein

Abstract: Dyslipidemia is a prominent feature of type 2 diabetes and insulin resistance that contributes to increased atherosclerosis and cardiovascular disease (CVD) risks under these conditions. Incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) have recently been developed and are approved for clinical use for treatment of type 2 diabetes. Besides improved glycemic control, other benefits are being increasingly appreciated, one of which is improved plasma lipid profile. This review aims to summarize the evidence and potential mechanism of such agents in humans in modulating fasting and postprandial lipoprotein metabolism.

Cite this article as:

Xiao Changting, Dash Satya and F. Lewis Gary, Mechanisms of Incretin Effects on Plasma Lipids and Implications for the Cardiovascular System, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (4) . https://dx.doi.org/10.2174/187152512803530315